Synthetic Human Parathyroid Hormone 1-34 vs Calcitriol and Calcium in the Treatment of Hypoparathyroidism
1996; American Medical Association; Volume: 276; Issue: 8 Linguagem: Inglês
10.1001/jama.1996.03540080053029
ISSN1538-3598
Autores Tópico(s)Thyroid Cancer Diagnosis and Treatment
ResumoObjective. —To test the hypothesis that treatment with human parathyroid hormone 1-34 (PTH 1-34) can maintain normal serum calcium without hypercalciuria in patients with hypoparathyroidism. Design. —Randomized crossover trial lasting 20 weeks. Each 10-week arm consisted of a 2-week inpatient dose-adjustment phase followed by an 8-week outpatient phase. Setting. —Tertiary care center. Patients. —A total of 10 patients with hypoparathyroidism were enrolled consecutively over a 15-month period. Half of the patients were prior National Institutes of Health patients, and the other 5 patients were referred from outside physicians. Interventions. —A dose of PTH 1-34 was administered each morning by subcutaneous injection. Calcitriol was given orally twice daily with supplemental calcium carbonate. Main Outcome Measures. —Serum and urine calcium and phosphorus levels. Results. —Once-daily treatment with PTH 1-34 maintained serum calcium in the normal range with decreased urine calcium excretion ( P <.05 at 2 weeks and P <.01 at 10 weeks) compared with calcitriol treatment. Biochemical markers of bone turnover increased significantly ( P <.01 at 10 weeks) during PTH 1-34 treatment. Conclusions. —Treatment of hypoparathyroidism with PTH 1-34 reduces urine calcium excretion compared with treatment with calcitriol and calcium.
Referência(s)